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New York and Brooklyn, New York; Berlin, Germany; Rochester, Minnesota; and Boston, MassachusettsObjectives Our aim was to study the impact of delay from symptom onset to ﬁrst coronary device
on infarct size and clinical outcomes at 30 days and 1 year in patients with ST-segment elevation
myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Background Longer delay from symptom onset to reperfusion has been linked to increased mortality
and worse clinical outcome. The mechanisms underpinning this association are not entirely clear.
Methods The INFUSE-AMI trial (INFUSE-Anterior Myocardial Infarction) randomized patients with
anterior STEMI undergoing primary percutaneous coronary intervention with bivalirudin
anticoagulation within 5 h of symptom onset to intralesion (IL) bolus abciximab versus no abciximab
and to thrombus aspiration versus no aspiration. The primary endpoint was contrast magnetic
resonance infarct size (IS) (percentage of left ventricular mass) at 30 days. Time to reperfusion was
classiﬁed as <3 versus 3 h.
Results There were 280 patients (62%) with <3-h delay and 170 patients (38%) with 3-h delay.
Patients with longer delay were signiﬁcantly older, more often women, and diabetic. Earlier
reperfusion was not associated with higher rates of ﬁnal Thrombolysis In Myocardial Infarction ﬂow
grade 3 or myocardial blush grade 2/3, but was an independent predictor of smaller IS (p ¼ 0.02 by
multivariable linear regression). Mortality at 1 year was reduced in patients with shorter delay to
reperfusion (4.0% vs. 9.2%, p ¼ 0.02).
Conclusions In patients with large anterior myocardial infarction undergoing relatively early reperfusion,
longer delays to reperfusion were associated with larger IS and 1-year mortality, but not with reduced
reperfusion success. (The INFUSE - Anterior Myocardial Infarction [AMI] Study; NCT00976521)
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734Primary percutaneous coronary intervention (PCI) in pa-
tients with ST-segment elevation myocardial infarction
(STEMI) results in greater reperfusion success and lower
rates of death, reinfarction, and stroke compared with
ﬁbrinolysis (1). It is assumed that primary PCI translates
into greater myocardial salvage (2), particularly for the late
presenters who respond less often to ﬁbrinolysis than earlier
presenters (3). Delay from ischemic symptom onset to
reperfusion has been shown to be an important predictor of
outcomes, to a greater extent for ﬁbrinolysis than for primary
PCI (4).
Strategies geared to improve procedural success and reper-
fusion rates in STEMI have focused on prevention of distal
embolization of atherothrombotic debris from the lesion siteAbbreviations
and Acronyms
CMR = contrast magnetic
resonance
IL = intralesion
IQR = interquartile range
IS = infarct size
LAD = left anterior
descending artery
LV = left ventricular
MBG = myocardial blush
grade
MI = myocardial infarction
MVO = microvascular
obstruction
PCI = percutaneous coronary
intervention
SPECT = single-photon
emission computed
tomography
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial Infarction(5). Intralesion (IL) abciximab (6)
and manual thrombus aspiration
(7) were tested in this context
in the recently completed The
INFUSE-AMI trial (INFUSE-
Anterior Myocardial Infarction)
(8,9). Using the INFUSE-AMI
database, we thus sought to eval-
uate whether the delay from
symptom onset to reperfusion af-
fects outcome after primary PCI
when these modalities are used
and whether the effect is mediated
via a larger infarct size (IS), as
determined by contrast magnetic
resonance (CMR).
Methods
The INFUSE-AMI Study has
been described in detail (9). In
brief, 452 patients with anterior
STEMI and an anticipated symp-
tom onset to reperfusion time of
<5 h undergoing primary PCI
with bivalirudin anticoagulationwere randomized in a 2  2 factorial design to an IL
abciximab bolus delivered at the site of the infarct lesion via
the ClearWay Rx catheter (Atrium Medical, Hudson, New
Hampshire) or no abciximab and to thrombus aspiration
using the Export catheter (Medtronic, Minneapolis, Min-
nesota) or no thrombus aspiration. The primary endpoint
of the study was IS, measured at 30 days by CMR and
expressed as the percentage of left ventricular (LV) mass in
patients assigned to IL abciximab or no abciximab, pooled
across strata of thrombus aspiration. The secondary major
endpoint was IS in patients assigned to aspiration or no
aspiration, pooled across strata of IL abciximab. All patients
received aspirin and clopidogrel or aspirin and prasugrel. In a
subset of patients, CMR was also performed at 5 days aftermyocardial infarction (MI) in a subset of patients to measure
extent of microvascular obstruction (MVO), expressed as the
percentage of LV mass (9). Major adverse cardiac and ce-
rebral events, consisting of death, reinfarction, stroke, or
ischemia-driven target vessel revascularization were recorded
at 30 days and 1 year, and bleeding was assessed using
various scales from previous clinical trials (10–12).
Markers of reperfusion were assessed at independent,
blinded core electrocardiography (ST-segment resolution)
and angiography (Thrombolysis In Myocardial Infarction
[TIMI] ﬂow, corrected TIMI frame counts, and myocar-
dial blush grade [MBG]) core laboratories at the Cardio-
vascular Research Foundation, using standard deﬁnitions
(10). MBG was assessed according to the densitometric
method, which evaluates the maximal intensity of con-
trast penetrating the infarct zone, compared with unaf-
fected territories (13). TIMI ﬂow grade 3 was considered
successful epicardial reperfusion, and MBG grade 2/3
was considered successful microcirculatory (myocardial)
reperfusion (14).
Statistical analysis. Continuous variables are presented as
mean with SD or median with interquartile range and were
compared with the Wilcoxon rank sum test. Categorical
variables are presented as proportions and were compared
with the chi-square or Fisher exact test. Survival curves for
time-to-event variables were constructed on the basis of all
available follow-up data with Kaplan-Meier methodology
and were compared using the log-rank test. Multivariable
linear regression was performed to determine the inde-
pendent predictors of 30-day IS. The following variables
were entered into the model: symptom to ﬁrst device time
(as a continuous variable), age, sex, diabetes, hypertension,
hyperlipidemia, current smoker, body mass index, baseline
white blood cell count, estimated creatinine clearance, prox-
imal versus mid left anterior descending artery (LAD) loca-
tion, number diseased epicardial coronary arteries, collaterals
present, baseline TIMI ﬂow grade 0/1 versus ﬂow grade 2/3,
ﬁnal TIMI ﬂow grade 3 versus ﬂow grade <3, IL abciximab
randomization, aspiration randomization, and interaction
term TIMI ﬂow  delay (<3 h vs. 3 h). Signiﬁcance level
was set at 0.05. All analyses were performed with SAS soft-
ware version 9.2 (SAS Institute, Cary, North Carolina).
Results
The primary endpoint of the study was previously reported
(9). IL abciximab compared with no IL abciximab reduced
30-day IS by 16%, from 17.9% (interquartile range [IQR]:
10.3% to 25.4%) to 15.1% (IQR: 6.8% to 22.7%) (p ¼ 0.03).
There was no signiﬁcant difference in IS with thrombus
aspiration.
Among the 450 patients enrolled in the study with
reperfusion timing data, 280 (62%) had a <3-h delay from
symptom onset to ﬁrst device and 170 (38%) had a delay
Table 1. Baseline Clinical Characteristics Stratiﬁed by Delay to Reperfusion
Delay to
Reperfusion <3 h
(n ¼ 280)
Delay to
Reperfusion 3 h
(n ¼ 170) p Value
Patient characteristics
Age, yrs 60.0 (51.0–69.0) 62.0 (53.0–73.0) 0.02
Male 81.4 (228/280) 61.2 (104/170) <0.0001
BMI, kg/m2 26.6 (24.0–29.4) 26.8 (23.9–29.4) 0.78
Heart rate, beats/min 75.0 (65.0–86.5) 80.0 (70.0–90.0) 0.005
Systolic BP, mm Hg 138.0 (120.0–154.0) 140.0 (122.5–156.5) 0.19
Killip class I 79.2 (221/279) 85.3 (145/170) 0.11
LVEF, % (investigator
estimate)
40.0 (35.0–50.0) 40.0 (35.0–50.0) 0.96
LVEF <40% 31.6 (83/263) 31.4 (49/156) 0.97
Medical history
Medically treated
hypertension
30.4 (85/280) 33.5 (57/170) 0.48
Medically treated
hyperlipidemia
15.8 (44/279) 15.3 (26/170) 0.89
Diabetes mellitus 8.6 (24/279) 15.3 (26/170) 0.03
Insulin treated 6.1 (17/278) 12.9 (22/170) 0.01
Previous myocardial
infarction
2.5 (7/279) 1.8 (3/170) 0.75
Previous PCI 0.0 (0/280) 0.0 (0/170) N/A
Previous CABG 25.9 (68/263) 17.9 (29/162) 0.06
Family history of
premature CAD
1.1 (3/279) 0.6 (1/169) 1.00
Previous congestive
heart failure
2.5 (7/279) 1.8 (3/170) 0.75
Smoking 62.5 (172/275) 57.1 (97/170) 0.25
Peripheral vascular
disease
1.4 (4/279) 1.8 (3/170) 1.00
History of stroke
or TIA
1.1 (3/279) 1.2 (2/170) 1.00
History of renal
insufﬁciency
0.7 (2/280) 0.0 (0/169) 0.53
Values are % (n) or median (interquartile range).
BMI ¼ body mass index; BP ¼ blood pressure; CABG ¼ coronary artery bypass grafting;
CAD ¼ coronary artery disease; LVEF ¼ left ventricular ejection fraction; N/A ¼ not available;
PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
Table 2. Procedural Characteristics Stratiﬁed by Delay to Reperfusion
Delay to
Reperfusion <3 h
(n ¼ 280)
Delay to
Reperfusion 3 h
(n ¼ 170) p Value
Total ischemic
time, min
128.0  28.0 240.5  38.6 <0.0001
Door-to-device
time, min
42.0 (32.0–59.5) 53.0 (38.0–83.0) <0.0001
Baseline TIMI
ﬂow grade
0.52
0 or 1 70.7 (198/280) 73.5 (125/170)
2 or 3 29.3 (82/280) 26.5 (45/170)
Final TIMI
ﬂow grade
0 or 1 1.8 (5/280) 2.4 (4/170) 0.73
2 or 3 98.2 (275/280) 97.6 (166/170) 0.73
3 92.5 (259/280) 89.4 (152/170) 0.76
Final myocardial
blush grade
0 or 1 17.9 (50/280) 20.1 (34/169) 0.55
2 or 3 82.1 (230/280) 79.9 (135/169) 0.55
2 11.8 (33/280) 12.4 (21/169) 0.84
3 70.4 (197/280) 67.5 (124/169) 0.52
Corrected TIMI
frame count
20.00 (16.00–26.00) 20.00 (16.00–25.00) 0.67
Values are % (n), mean  SD, or median (interquartile range).
TIMI ¼ Thrombolysis In Myocardial Infarction.
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7353 h. As shown in Table 1, patients with longer ischemic
time were more likely to be older and women and have
higher heart rate and diabetes mellitus. Approximately two-
thirds of the subjects in each group had proximal LAD
occlusion (p ¼ 0.11). Total ischemic time was 128.0  28.0
min versus 240.5  38.6 min, respectively (p ¼ 0.0001).
Longer door-to-device time was responsible for onlyw11min
of this delay (Table 2). Patients with longer delays were also
more likely to have Q waves on a pre-PCI electrocardiogram
(55.0% vs. 37.2%, p ¼ 0.0002).
A shorter delay to reperfusion was not associated with
higher rates of ﬁnal TIMI ﬂow grade 3 or MBG 2/3 (Ta-
ble 2). IS at 30 days (percentage of LV mass) was marginally
smaller in patients with a shorter delay to reperfusion
(16.4%; IQR: 6.5% to 22.9% vs. 18.1%; IQR: 10.5% to24.8%, respectively; p ¼ 0.07) (Table 3). By linear regres-
sion, earlier reperfusion was an independent predictor of
smaller 30-day IS (Table 4). In the 5-day CMR substudy,
there was no difference in MVO or other CMR parameters
as a function of time to reperfusion.
As shown in Table 5 and Figures 1 and 2, patients
with longer delay to reperfusion had signiﬁcantly higher
rates of major adverse cardiac and cerebral events at
30 days and 1 year, driven by higher rates of cardiac and
all-cause death. There were no signiﬁcant differences be-
tween the groups with respect to bleeding complications,
MI, new-onset or recurrent severe heart failure, or stent
thrombosis.
To better understand the complex relationship between
delay to reperfusion and outcome, we examined MBG 2/3,
ST-segment resolution >70%, IS, and 1-year death in
patients grouped in 6-h delay groups (Fig. 3A). There were
3, 99, 178, 84, 73, and 12 patients with time from symp-
tom onset to delay of 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5,
and 5 to 6 h, respectively. There was a statistically signif-
icant (p ¼ 0.02) trend for greater (albeit modest) average
30-day IS with increasing delay, as well as a signiﬁcant
trend toward higher mortality (p ¼ 0.03). These results
were conﬁrmed in the subset of 254 patients with TIMI
ﬂow grade 0/1 at baseline angiography and follow-up
CMR at 30 days, for whom delay to reperfusion was the
most meaningful (Fig. 3B).
Table 3. CMR Parameters at 5 and 30 Days Stratiﬁed by Delay to
Reperfusion
Delay to
Reperfusion <3 h
Delay to
Reperfusion 3 h p Value
CMR at 5 days 110 59
Total MVO, g 0.8 (0.0–3.8) 0.7 (0.0–3.8) 0.85
MVO (% of total
myocardial mass)
0.56 (0.00–2.39) 0.48 (0.00–2.57) 0.97
MVO (% of total
infarct mass)
3.3 (0.0–9.6) 2.9 (0.0–8.9) 0.92
Total abnormal wall
motion score
8.0 (4.0–10.0) 9.0 (6.0–11.0) 0.25
Total infarct mass, g 31.8 (13.6–50.5) 32.1 (19.2–46.2) 0.77
Infarct size, % of LV mass 21.0 (11.2–30.6) 23.5 (15.9–33.2) 0.13
LVEF, % 48.1 (41.1–54.1) 47.5 (40.3–52.4) 0.36
CMR at 30 days N ¼ 229 N ¼ 130
Total myocardial mass, g 130.9 (110.7–154.2) 127.3 (103.3–151.1) 0.08
Total infarct mass, g 21.4 (7.3–34.2) 20.5 (12.8–31.1) 0.77
Infarct size, % of LV mass 16.4 (6.5–22.9) 18.1 (10.5–24.8) 0.07
Total abnormal wall
motion score
6.4  4.9 (238) 7.2  4.7 (133) 0.09
LVEDV, ml 175.5 (150.6–207.0) 167.9 (137.5–209.0) 0.13
LVEF, % 49.8  10.8 (230) 48.7  9.5 (130) 0.34
Values are n or median (interquartile range), or mean  SD.
CMR ¼ contrast magnetic resonance; LV ¼ left ventricular; LVEF ¼ left ventricular ejection
fraction; LVEDV ¼ left ventricular end-diastolic volume; MRI ¼ magnetic resonance imaging;
MVO ¼ microvascular obstruction.
Table 4. Independent Predictors of 30-Day Infarct Size by Linear
Regression Analysis
Multivariate Predictors Coefﬁcient SE p Value
Intercept 9.39 4.05 0.0213
Baseline WBC count 0.54 0.13 0.0001
Abciximab infusion 2.58 1.01 0.0108
Symptom onset to ﬁrst device time, min 0.02 0.01 0.0175
Proximal LAD location 5.39 1.07 <0.0001
Baseline TIMI 0/1 6.07 1.11 <0.0001
Age 0.13 0.05 0.0038
Sex, male 2.09 1.22 0.0880
LAD ¼ left anterior descending artery; TIMI ¼ Thrombolysis In Myocardial Infarction;
WBC ¼ white blood cell.
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736Among the 372 patients who survived to 30 days and
underwent CMR (263 with a delay <3 h and 109 with
a delay 3 h), there were no signiﬁcant differences in
the rates of 1-year death (1.9% vs. 1.9%, p ¼ 0.97) or
death/MI (2.3% vs. 2.8%, p ¼ 0.78). These data suggest
that most of the mortality risk in the longer delay groupTable 5. Clinical Outcomes at 30 Days and 1 Year Stratiﬁed by Delay to Reperfu
Event
30 Days
Delay to
Reperfusion <3 h
Delay to
Reperfusion 3 h
MACCEy 2.2 (6) 7.2 (12)
Death 1.4 (4) 5.4 (9)
Cardiac death 1.4 (4) 5.4 (9)
MI 0.4 (1) 1.3 (2)
Death/MI 1.8 (5) 6.0 (10)
Bleeding (TIMI major or minor) 2.2 (6) 2.5 (4)
New-onset severe heart failure 3.2 (9) 4.8 (8)
Any revascularization 1.1 (3) 2.5 (4)
Stent thrombosis (def þ prob) 1.1 (3) 1.3 (2)
Values are % (n). *p Value from the log-rank test. yMACCE deﬁned as a composite of all-cause
or stroke.
Def ¼ deﬁnite; MACCE ¼ major adverse cardiac and cerebrovascular event(s); MI ¼ myocardial infarwas manifested earlier than 30 days (as also seen in
Fig. 2).Discussion
In the present analysis from the INFUSE-AMI Study, we
studied the impact of delay to reperfusion on infarct size
and clinical outcomes in patients with STEMI. The main
ﬁndings are that in patients with large anterior STEMI
presenting relatively early after symptom onset, longer delays
to reperfusion were not associated with decreased reperfu-
sion success or greater MVO, but were associated with
increased IS and mortality. These ﬁndings were conﬁrmed
in the subset with TIMI ﬂow grade 0/1 in the infarct-related
artery at baseline angiography.
The relationship between delays to reperfusion and clin-
ical outcomes after STEMI has been analyzed extensively
after treatment with both ﬁbrinolysis and primary PCI.
Because symptom onset may be difﬁcult to time preciselysion
1 Year
p Value*
Delay to
Reperfusion <3 h
Delay to
Reperfusion 3 h p Value*
0.009 6.2 (17) 13.5 (22) 0.008
0.02 4.0 (11) 9.2 (15) 0.02
0.02 2.5 (7) 8.6 (14) 0.004
0.28 0.7 (2) 1.3 (2) 0.57
0.02 0.8 (2) 0.0 (0) 0.29
0.86 3.7 (10) 4.3 (6) 0.95
0.41 5.1 (14) 6.8 (11) 0.45
0.26 3.9 (10) 6.6 (10) 0.19
0.89 1.1 (3) 2.6 (4) 0.27
death, reinfarction (Q-wave and non–Q-wave), ischemia-driven target vessel revascularization,
ction; prob ¼ probable; TIMI ¼ Thrombolysis In Myocardial Infarction.
Figure 1. Mortality and Morbidity Rates at 1 Year According to Reperfusion
Delay (<3 vs. 3 h)
Patients undergoing reperfusion within 3 h of symptom onset had signiﬁ-
cantly lower rates of all-cause death, cardiovascular death, major adverse
cardiac events, and major adverse cardiac and cerebrovascular events than
patients with later reperfusion. MACCE ¼ major adverse cardiac and cere-
brovascular events (all cause death, reinfarction [Q-wave and non–Q-wave],
ischemia-driven target vessel revascularization, or stroke); MACE ¼ major
adverse cardiac events (death, reinfarction, new-onset heart failure, or reho-
spitalization for heart failure); CV ¼ death/cardiovascular death.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 7 , 2 0 1 4 Guerchicoff et al.
J U L Y 2 0 1 4 : 7 3 3 – 4 0 Delay to Reperfusion and Clinical Outcome
737and because infarct-artery patency may be restored before
initiation of pharmacological or mechanical reperfusion
therapy, most of the emphasis has been placed on the
delay attributable to systems of care (i.e. “door-to-device”
[15] or “door-to-needle” [16]). Consequently, professionalFigure 2. Cumulative Survival at 1 Year According to Reperfusion
Delay (<3 vs. 3 h)
Patients undergoing reperfusion within 3 h of symptom onset (red line) had
signiﬁcantly lower rates of death at 1 year than patients with later reperfusion
(blue line). The curves separated early, by 30 days, and remained parallel
thereafter. CI ¼ conﬁdence interval; HR ¼ hazard ratio.guidelines recommend that reperfusion be achieved within a
certain interval, indexed to ﬁrst medical contact rather than
to symptom onset (17,18). Yet, in this context, 2 series
examining changes in door-to-device time in the past decade
in >50,000 patients concluded that continuing reduction
in the hospital-related delay to reperfusion had little effect
on mortality (19,20). Delayed door-to-balloon times may
reﬂect greater patient illness and complexity, such as the
need to stabilize heart failure or treat ventricular arrhythmias
before cardiac catheterization. Administrative registry data-
bases are typically unable to account for many of these
events, and all potential confounders are not collected in
even the most rigorously performed clinical trials. Thus,
total ischemic time (symptom onset to balloon or ﬁrst
device) may be a better metric to examine the effect of time
on clinical outcomes.
De Luca et al. (21) examined the total ischemic time in a
large cohort of STEMI patients treated with primary PCI.
After adjusting for age, sex, diabetes mellitus, and previous
revascularization, every additional 30 min of reperfusion
delay increased 1-year mortality by 8% (hazard ratio: 1.01
to 1.15, p ¼ 0.04). In an analysis of 2 large STEMI trials
encompassing >4,500 patients, Brodie et al. (22) high-
lighted the interaction between delay from symptom onset
to presentation and delay from arrival to reperfusion. Only
in patients with a short delay to presentation (90 min
from symptom onset) did a shorter delay to reperfusion
affect 1-year mortality (1.9% vs. 3.8%, p ¼ 0.029 vs. 4.0%
vs. 4.6%, p ¼ 0.47 in those who presented later). The pre-
sent contemporary study supports the relationship between
early reperfusion and improved survival after primary PCI in
patients with large anterior STEMI.
Despite a wealth of clinical data from these randomized
and observational studies, little information exists regarding
the mechanism for the higher mortality associated with
delayed reperfusion. In a randomized trial of ﬁbrinolysis
versus primary PCI in which IS was assessed by technetium-
99 sestamibi single-photon emission computed tomography
(SPECT) imaging, IS was independent of total ischemic
time with PCI but not with ﬁbrinolysis (3). Conversely, in
a previous analysis of predictors of infarct size determined
by SPECT scintigraphy in nearly 1,200 patients at a median
of 23 days after primary PCI, Stone et al. (23) identiﬁed
LAD infarct, longer door-to-device time, male sex, and
pre-PCI TIMI ﬂow grade 0/1 as the principal correlates of
IS (all p < 0.001). In the INFUSE-AMI Study, delay from
symptom onset to reperfusion was an independent predictor
of larger IS at 30 days (as measured by CMR, which is more
sensitive than SPECT for the detection of small areas of
infarction) and correlated with 1-year mortality. We have
also previously shown from this study that 30-day IS cor-
related with subsequent death between 30 days and 1 year
(3.4% vs. 0.0% in patients with larger than vs. equal to or
smaller than the median IS of 17%, respectively, p ¼ 0.02)
Figure 3. Average Infarct Size and Frequency of Myocardial Blush Grade 2/3, Complete (>70%) ST-Segment Resolution or 1-Year Death According to Hourly
Intervals of Reperfusion Delay
(A) Average infarct size (IS) (percentage of left ventricular mass) and frequency of myocardial blush grade (MBG) 2/3, complete (>70%) ST-segment resolution (STRES),
or 1-year death according to hourly intervals of reperfusion delay. Dividing the delay to reperfusion into hourly intervals, we tabulated the average infarct size (orange
columns) assessed by cardiac magnetic resonance, frequency of obtaining MBG grade 2 or 3 (blue columns) and of having >70% ST-segment resolution (red
columns) in each of these intervals. The mortality rate at 1 year is overlaid on these values (purple line). There was a signiﬁcant trend toward greater infarct size and
mortality as time to reperfusion increased, without differences in frequencies of favorable angiographic or electrocardiographic outcomes. (B) Average IS (percentage
of left ventricular mass) and frequency of MBG 2/3, complete (>70%) STRES or 1-year death according to hourly intervals of reperfusion delay. Analyzing only patients
with baseline Thrombolysis In Myocardial Infarction 0-1 ﬂow in the infarct artery and dividing the delay to reperfusion into hourly intervals, we tabulated average
infarct size (orange columns) assessed by cardiac magnetic resonance and the frequency of obtaining an MBG of 2 or 3 (blue columns) and of having >70% STRES
(red columns) in each of these intervals. The mortality rate at 1 year is overlaid on these values (purple line). There was a signiﬁcant trend toward greater IS and
mortality as time to reperfusion increased, without differences in frequencies of favorable angiographic or electrocardiographic outcomes.
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738(24). These data reinforce the relationship between IS and
mortality after primary PCI and suggest that efforts to
reduce the time delay to reperfusion in patients with large
anterior STEMI presenting relatively early are warranted.
Previous studies have shown that earlier time to reper-
fusion with primary PCI is associated with greater reperfu-
sion success, as assessed by MBG 2/3 (25). This was not
observed in the present study, in which all patients werereperfused relatively early. Thus, the reduction in IS in
patients reperfused early in the present study was not due to
better myocardial perfusion, but more likely to interruption
of the infarct wave front from the subendocardium to the
subepicardium, before becoming transmural (26).
Study limitations. In addition to the larger IS in patients
with longer delay to reperfusion, differences in baseline
characteristics, such as age, diabetes, and other unmeasured
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739confounders may have contributed to the higher mortality in
these patients, which mostly occurs early after STEMI. The
limited number of deaths in the present study precludes a
comprehensive multivariable analysis to determine the pre-
dictors of survival. Moreover, many patients who died did
not have IS assessment because they did not reach the
30-day CMR time point. We recognize that the lack of
association between delay to reperfusion and MBG or
ST-segment resolution may represent the consequence of
a homogeneous STEMI population treated within a short
interval from symptom onset. The present study also rep-
resents a post-hoc analysis from a carefully controlled,
randomized trial designed to determine the effect of intra-
lesional abciximab delivery and thrombus aspiration on IS.
Although patient enrollment was stratiﬁed for delay
to presentation of <3 or >3 h, the analysis was not corrected
for the propensity to present in each of these categories. Thus,
these results should be considered hypothesis generating.
Conclusions
Despite these limitations, the present study demonstrates
that among patients with a large anterior MI presenting
relatively early after symptom onset and treated by con-
temporary primary PCI, longer delay to reperfusion is linked
to greater IS and higher mortality. This effect appears not
to be mediated by less successful reperfusion. As median
door-to-device times have now been reduced in many hos-
pital systems to <60 min, if STEMI outcomes are to be
further improved, the emphasis should shift to aggressive
public education focusing on minimizing the delay to pre-
sentation and ensuring access to reperfusion for all eligible
patents.
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